Meghan Morgan-Smith | Director, Therapeutic Area
ICON PLC
A molecular neurobiologist with over 16 years of experience in academic institutions and CROs. Director in ICON’s Centre for Rare Disease with broad expertise in rare diseases and precision medicine trials. 7 years of experience in clinical program project management covering phase I-III trials in rare and non-rare indications
Appearances:
Day 2 - Thursday 24 October @ 11:10
Practical Approaches to Including Patient Advocacy Organizations in Your Drug Development Program: Not Only Why, But How
The session will discuss the ways Patient Advocacy Organizations play a vital role in all parts of the drug development process, from pre-clinical to post marketing in rare diseases. The discussion will highlight the essential tools needed to harness the power of collaborative partnerships to move science from bench to bedside
Learning outcomes:
-Understand how patient advocacy organizations drive therapeutic development in the rare disease space
-How to effectively engage and partner with patient advocacy organizations to develop meaningful treatments
-Gain insight into the “how, when and where” patient advocacy can significantly impact the drug development process
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events